ESR1 and breast cancer: Kaplan–Meier analysis revealed that RFS in patients with ERα-positive breast cancer treated with endocrine therapy is significantly decreased in 463 patients with high survivin expression in tumors as compared to 465 patients with low NgBR expression in tumors (p < 0.05).